Jean Francois Leonard
Affiliation: Sanofi-Aventis Deutschland GmbH
- Proteomic characterization of the effects of clofibrate on protein expression in rat liverJean Francois Leonard
Drug Safety Evaluation, Sanofi Aventis, Vitry sur Seine, France
Proteomics 6:1915-33. 2006..Differential effects on those variants could result from specific PTM and could be a specific molecular signature of the clofibrate-induced protein expression modulation in rat liver...
- Optimization of SELDI for biomarker detection in plasmaJean Francois Leonard
Disposition, Safety and Animal Research, sanofi aventis R and D, Vitry sur Seine, France
Methods Mol Biol 691:351-68. 2011..Last, a systematic evaluation of technical bias such as the spot and chip position and the bioprocessor sequence number may be achieved using the appropriate multivariate statistical analyses...
- Early drug safety evaluation: biomarkers, signatures, and fingerprintsRuth Roberts
Aventis Pharma, Drug Safety Evaluation, Centre de Recherche de Paris, Paris, France
Drug Metab Rev 35:269-75. 2003..the efficacious dose can provide clues on MOA for the toxicity and may allow differentiation of the pathways of the toxic response from those required for pharmacological activity...